Medigene AG: Medigene's Drug Veregen® Launched in Canada
Medigene AG / Medigene's Drug Veregen® Launched in Canada . Processed and
transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely
responsible for the content of this announcement.
Martinsried/Munich, July 17, 2014. Medigene AG (MDG1, Frankfurt, Prime
Standard) announces the launch of its drug Veregen^® (Sinecatechins Ointment,
10%) for the treatment of genital warts in Canada through the marketing
partner Paladin Labs Inc. (who acquired Triton Pharma). Within the scope of
the license agreement, Medigene receives sales milestone payments as well as
royalties on Veregen^® sales.
Up to now, Veregen^® is available in the USA, in 15 European countries
(Germany, Austria, Switzerland, Spain, Serbia, the Netherlands, Belgium,
Norway, Sweden, Denmark, Finland, Czech Republic, Slovakia, Hungary, and
Poland), and in Taiwan. The drug has obtained market approval in a number of
additional countries. Several marketing partnership agreements have been
concluded in Europe, Asia, and America.
About Veregen^®: Veregen^®, a topical treatment for external genital or
perianal warts, contains a concentrate of catechins with a complex defined
composition extracted from green tea leaves. Sinecatechins 10% & 15% Ointment
(Veregen^®) has been included in the 2012 European Guideline for the
Management of Anogenital Warts. In addition, in its current Sexually
Transmitted Diseases Treatment Guidelines, the US Centers for Disease Control
and Prevention includes Sinecatechins 15% Ointment (Veregen^®) as a possible
option for treating genital warts.
About Paladin Labs Inc.: Paladin Labs Inc., headquartered in Montreal, Canada,
is a specialty pharmaceutical company focused on acquiring or in-licensing
innovative pharmaceutical products for Canadian and select emerging markets.
Paladin has a focused marketing and sales organization that has helped it
evolve into one of Canada's leading specialty pharmaceutical companies.
Paladin is an operating company of Endo International plc, a global specialty
healthcare company focused on improving patients' lives while creating
shareholder value. Learn more at www.endo.com.
Medigene AG is a publicly listed (Frankfurt: MDG1, prime standard)
biotechnology company headquartered in Martinsried near Munich, Germany.
Medigene concentrates on the development of personalized T cell
immunotherapies with focus on haematological malignancies. Medigene is the
first German biotech company to have revenues from a marketed product, which
is distributed by commercial partners. Medigene has various drug candidates in
clinical development and it is developing highly innovative treatment
platforms. For more information, please visit www.medigene.de.
This press release contains forward-looking statements representing the
opinion of Medigene as of the date of this release. The actual results
achieved by Medigene may differ significantly from the forward-looking
statements made herein. Medigene is not bound to update any of these
forward-looking statements. Medigene^® and Veregen^® are registered trademarks
of Medigene AG. Polyphenon E^® is a trademark of Mitsui Norin Co., Ltd. These
trademarks may be owned or licensed in select locations only.
Julia Hofmann, Anja Clausnitzer
Tel.: +49 - 89 - 20 00 33 - 33 01
To unsubscribe from the press release distribution list, please go to:
Press release as PDF
This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf
of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for
the content, accuracy and originality of the information contained therein.
Source: Medigene AG via Globenewswire
--- End of Message ---
Lochhamer Strasse 11 Martinsried / München Germany
WKN: A1X3W0;ISIN: DE000A1X3W00;
Listed: Freiverkehr in Börse Stuttgart,
Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg,
Freiverkehr in Börse Berlin,
Freiverkehr in Börse Düsseldorf,
Freiverkehr in Bayerische Börse München,
Freiverkehr in Niedersächsische Börse zu Hannover,
Prime Standard in Frankfurter Wertpapierbörse,
Regulierter Markt in Frankfurter Wertpapierbörse;
Press spacebar to pause and continue. Press esc to stop.